[Novel agents for acute myeloid leukemia not yet approved in Japan].

While acute myeloid leukemia (AML) treatment has significantly advanced in recent years, many promising novel agents remain unapproved in Japan. This review focuses on menin inhibitors and covers IDH inhibitors, oral azacitidine, antibody-drug conjugates, bispecific antibodies, radioisotope therapies, and CAR-T cell therapies for AML. Menin inhibitors, which are particularly effective against AML with KMT2A rearrangements or NPM1 mutations, have shown promising results in clinical trials. These novel agents may expand treatment options and improve outcomes for AML patients.